Navigation Links
Vicus Therapeutics Announces Initiation of Phase 2 Trial to Evaluate VT-122 in Patients with Liver Cancer Receiving Nexavar
Date:12/27/2010

ue, weakness, pain, dyspnea, nausea, malaise, anxiety, depression and poor performance status.(1,2)  This symptom cluster is  further associated with poor tolerance, adherence and response to anti-cancer therapy, disease progression and reduced life expectancy.(1,2)

About Hepatocellular Carcinoma

Hepatocellular carcinoma is the most common form of liver cancer and is responsible for about 90 percent of the primary malignant liver tumors in adults.  Liver cancer is the sixth most common cancer in the world and the third leading cause of cancer-related deaths globally.  

About VT-122

VT-122 is a novel investigational combination of etodolac and propranolol that targets pathways associated with cancer-induced systemic inflammation, a suspected cause of cancer cachexia.(1,2) VT-122 has demonstrated the ability to increase lean body mass (muscle) and lower other markers of systemic inflammation in a Phase 2 trial of patients with advanced lung cancer.(3) Preclinical and clinical studies show that propranolol and etodolac, when used individually, attenuate systemic inflammation, hypermetabolism, and weight loss.(4,5,6)  Furthermore, non-clinical studies show that this combination acts synergistically to attenuate systemic inflammation, activate cellular immunity, reduce metastasis, and increase animal survival.(7)

About Nexavar

Nexavar is approved in the U.S. for the treatment of patients with unresectable liver cancer and for the treatment of patients with advanced kidney cancer.  Nexavar inhibits both the tumor cell and tumor vasculature.  In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two impo
'/>"/>

SOURCE Vicus Therapeutics, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. King Pharmaceuticals and Pain Therapeutics Announce Resubmission of New Drug Application for REMOXY®
4. PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis
5. Silence Therapeutics Provides Year-end Update
6. Angelica Therapeutics Receives a $244,479 Qualified Therapeutic Discovery Project Grant for Its Anti-Cancer Drug
7. Talecris Biotherapeutics Enrolls Patients in Clinical Trial Evaluating Two Doses of PROLASTIN®-C
8. Osseon® Therapeutics Names Gary Coughlen, CPA as New Chief Financial Officer
9. Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinsons Disease
10. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
11. Nile Therapeutics Receives NASDAQ Notice; Will Request Hearing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 The American Association ... Medical Design and Manufacturing has joined the AAHomecare Corporate ... Harvey Diamond have been actively involved in ... as it has quickly grown into a major global ... like Drive allows AAHomecare to increase efforts on behalf ...
(Date:9/19/2014)... UBM Medica US announces that  ... help oncologists and other clinicians gain a better understanding ... targeted therapies and immunotherapies, discusses some of the latest ... Every September, Blood Cancer Awareness Month ... blood cancers—helping to increase survival rates and improve the ...
(Date:9/19/2014)... WOONSOCKET, R.I. , Sept. 19, 2014 ... (NYSE: CVS ), will speak before the National ...  Merlo will discuss the company,s recent move to stop selling ... to shape the future of health. "Dramatic changes ... consumers, health care providers and government," Merlo has said. "CVS ...
Breaking Medicine Technology:Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3
... Dec. 1, 2011 Arbor Pharmaceuticals announced today that it ... the U.S. Food and Drug Administration (FDA).  The recently ... the FDA which provides seven years of market exclusivity. ... status for this product primarily due to the safety ...
... Novelos Therapeutics, Inc. (OTCBB: NVLT) , a pharmaceutical company ... announced the pricing of an underwritten public offering of 9,840,000 ...  Each unit consists of one share of common stock and ... warrants will have an exercise price of $0.60 per share ...
Cached Medicine Technology:Arbor Pharmaceuticals Announces Filing of First NDA 2Novelos Therapeutics Prices $5.9 Million Public Offering 2
(Date:9/21/2014)... New York (PRWEB) September 21, 2014 ... continue to move forward in Pennsylvania’s Philadelphia Court ... to court documents, the proceeding’s next monthly meeting ... Litigation, case number 100300296) , “Our Firm is ... Risperdal lawsuits in this litigation. We are pleased ...
(Date:9/21/2014)... 2014 Best Cheap Hosting USA, one ... Arvixe, Bluehost and GreenGeeks are the best Reseller hosting ... good reseller hosting supplier. Actually, these companies have outperformed ... customer support. People can get the best web hosting ... , According to the manager, reseller hosting is a ...
(Date:9/21/2014)... September 21, 2014 Market ... (CAS 49562-28-9) Industry, 2009-2019 is a professional ... Chinese Fenofibrate (CAS 49562-28-9) industry. The report ... (CAS 49562-28-9) including its classification, application and ... China’s top manufacturers of Fenofibrate (CAS 49562-28-9) ...
(Date:9/21/2014)... September 21, 2014 More than ... been added over the past month to a ... serious cardiovascular injuries caused by the dialysis concentrate, ... updated on September 15th shows 2,089 cases filed ... District Court, District of Massachusetts. These claims were ...
(Date:9/21/2014)... Recently, BambooIndustry.com, an experienced producer of natural bamboo items, ... ( http://www.bambooindustry.com/products/bamboo-panel/ ). The company’s excellent panels are very ... at discounted prices now, from 10 to 30 percent ... are available in many specifications; they are promised ... is finely manufactured by qualified workers. They are specially ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4Health News:Best Cheap Hosting USA Announces The Best Reseller Hosting Suppliers In 2014 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 3Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 4Health News:Discounted Bamboo Panels For Sale At BambooIndustry.com 2
... in four teenagers who had meningitis during infancy will not ... in Archives of Disease in Childhood. ,The findings ... year olds across England and Wales, 461 of whom had ... ,The children were all taking part in a long ...
... Scientists of University College London have conducted a study ... is indeed responsible// for dyscalculia or in ... hope the findings will aid in the diagnosis and ... ,Dyscalculia is just as prevalent in the population as ...
... the Victorian disease tuberculosis is on the march. Figures released by ... percent in number of TB cases over the last year. ... on the 24th of March, are provisional and relate ... account for the highest proportion of cases (42 percent) but the ...
... Steriani Elavsky, women passing through their menopause are reported to ... improvements in heart and respiratory fitness are said to have ... ,This research was carried out on 164 inactive menopausal ... basis. One group was assigned to perform Yoga while the ...
... junior doctors' has been reduced in order to increase their ... medics found that cutting down working hours alone is not ... of rotas was essential. ,The Occupational and Environmental ... Auckland universities in New Zealand. ,In the UK, ...
... that the odds of firefighters dying from coronary heart disease ... 100 times higher than during non-emergency duties such as rescuing ... Harvard Medical School and colleagues say episodic physical and psychological ... of physical fitness appeared responsible for it. ,Even though ...
Cached Medicine News:Health News:Reason Behind Dyscalculia Revealed 2Health News:TB Cases on the Rise 2Health News:Rest for Doctors to Ensure Patients’ Safet 2Health News:New Study Reveals That Firefighters Are Prone To Heart Attack 2
... The D.O.R.C. Associate® is an ... a Peristaltic and Venturi pump, allowing ... mode for Phaco or Vitrectomy procedures.,The ... is a microprocessor-controlled vacuum system that ...
The D.O.R.C. CryoStar is the smart cryosurgical system that combines optimal performance with state-of-the-art automation. simple for O.R. staff to operate and maintain throughout every procedure....
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media. (Sterile, 10 ml.)...
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media.(Sterile, 10 ml.)...
Medicine Products: